Dr. Sapna P. Patel
Claim this profileMD Anderson Cancer Center
Expert in Skin Cancer
Studies Uveal Melanoma
13 reported clinical trials
25 drugs studied
Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
NRAS positive
2Uveal Melanoma
Stage IV
HLA-A positive
HLA-A negative
Affiliated Hospitals
Clinical Trials Sapna P. Patel is currently running
Darovasertib + Crizotinib
for Uveal Melanoma
This trial is testing a new drug combination (IDE196 and crizotinib) on patients with a specific type of eye cancer that has spread. The goal is to see if this combination can stop or slow down the cancer better than other treatments. Crizotinib has been used in treating various cancers with ALK gene rearrangements, showing high response rates.
Recruiting1 award Phase 2 & 38 criteria
SX-682 + Pembrolizumab
for Melanoma
Cancers attract myeloid-derived suppressor cells (MDSCs) that prevent our own immune responses from destroying the cancer. This study will be the first study to begin to determine if the newly discovered drug SX-682 can block cancers from attracting MDSCs. This first study will enroll participants with melanoma, as melanoma cancer has been shown to be able to attract MDSCs. The study will begin to determine if SX-682 is a safe and effective treatment of melanoma. It is thought that SX-682 will block MDSCs from going to the cancer, and thus will allow a patient's own immune system to attack the cancer. The first participants enrolled in the study will receive for 21 days SX-682 as monotherapy. After 21 days participants will receive pembrolizumab therapy (an approved immunotherapy for melanoma) in combination with SX-682 for up to approximately 2 years. Once the safe dose level of SX-682 in combination with pembrolizumab is determined, the remaining participants will be enrolled at the highest safe dose level of SX-682, in combination with pembrolizumab. These participants will receive the combination therapy and be evaluated in the study for approximately 2 years.
Recruiting1 award Phase 121 criteria
More about Sapna P. Patel
Clinical Trial Related1 year of experience running clinical trials · Led 13 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Sapna P. Patel has experience with
- Pembrolizumab
- Ipilimumab
- Nivolumab
- Aldesleukin
- Autologous CD8+ SLC45A2-specific T Lymphocytes
- Cyclophosphamide
Breakdown of trials Sapna P. Patel has run
Skin Cancer
Uveal Melanoma
Eye Cancer
Melanoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sapna P. Patel specialize in?
Sapna P. Patel focuses on Skin Cancer and Uveal Melanoma. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Sapna P. Patel currently recruiting for clinical trials?
Yes, Sapna P. Patel is currently recruiting for 3 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Sapna P. Patel has studied deeply?
Yes, Sapna P. Patel has studied treatments such as Pembrolizumab, Ipilimumab, Nivolumab.
What is the best way to schedule an appointment with Sapna P. Patel?
Apply for one of the trials that Sapna P. Patel is conducting.
What is the office address of Sapna P. Patel?
The office of Sapna P. Patel is located at: MD Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the MD Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.